Last reviewed · How we verify
NCT07096583
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
Phase 1, PHASE2 trial testing METR-NK cell（metabolic remodeling nature killer cells） in Ovary Cancer in 20 participants. Participants enrolled and being followed up; not accepting new ones.
30 July 2026
Quick facts
| Lead sponsor | Anhui Provincial Cancer Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 7 July 2025 |
| Primary completion | 30 July 2026 |
| Estimated completion | 30 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- METR-NK cell（metabolic remodeling nature killer cells）
Conditions studied
- Ovary Cancer — all drugs for Ovary Cancer →
Sponsor
Anhui Provincial Cancer Hospital
Who can join
Adults 18 to 70, female only, with Ovary Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the remission effect and safety of intravenous injection of METR-NK cells as adjuvant therapy on bone marrow suppression in patients with ovarian cancer after chemotherapy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options.
Hong SY, Cho A, Chae CS, You HJ. · · 2025 · PMID 41470247 · DOI 10.3390/medicina61122246
Verify or expand the search:
- PubMed search for NCT07096583
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovary Cancer
Currently open trials in the same condition.
- NCT07213193 — No-Stoma Policy in Advanced Ovarian Cancer Surgery · NA · recruiting
- NCT07084168 — Multimedia Aid for Genetic Testing in Gynecologic Oncology · NA · recruiting
- NCT06540729 — RC48 in Combination With AK104 and Bevacizumab in OCCC · Phase 2 · recruiting
- NCT06556342 — The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women · NA · recruiting
- NCT06331130 — Mesenteric Infiltration in Ovarian Cancer · recruiting
Other Anhui Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07371871 — A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Th · NA · not yet recruiting
- NCT07299890 — An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy · Phase 2 · not yet recruiting
- NCT07330596 — QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC · Phase 2 · recruiting
- NCT07197697 — A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ · Phase 2 · not yet recruiting
- NCT07195084 — To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07096583 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Cancer Hospital
- Last refreshed: 31 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096583.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing